Cleveland Clinic, Cleveland, Ohio 44195, USA.
J Urol. 2010 Feb;183(2):560-4. doi: 10.1016/j.juro.2009.10.049. Epub 2009 Dec 16.
While many primary care providers advocate routine screening urinalyses, a heme positive dipstick test often leads to a false-positive diagnosis of hematuria, or pseudohematuria. Thus, American Urological Association guidelines recommend urological evaluation for asymptomatic patients only for at least 3 red blood cells per high power field in 2 of 3 microscopic urinalyses. We determined the percentage of patients referred for asymptomatic hematuria undergoing unnecessary consultation and studies.
Patients were retrospectively identified if seen for initial consultation associated with CPT 599.7X, hematuria. Among these patients those referred for evaluation of asymptomatic nonmacroscopic hematuria were identified, and referral patterns, ancillary tests, procedures and findings were examined.
Of 320 new patient visits with diagnosis code 599.7X, 91 were referred for asymptomatic, nonmacroscopic hematuria. Of these patients only 37 (41%) had microscopic urinalyses before referral and only 22 (24%) had microscopic urinalyses showing 3 or more red blood cells per high power field. Of the 69 patients referred without confirmed microhematuria approximately 25% had true microhematuria and 15 with no true hematuria had undergone imaging before referral. The Medicare reimbursement value for the evaluation of these 69 patients was $44,901. Of these patients 35 underwent cystoscopy and only 1 (with true microhematuria) had a malignancy.
Positive dipstick heme tests should always be confirmed by microscopic urinalysis before urological referral or evaluation. Education of referring physicians regarding the American Urological Association guidelines could possibly help limit costly and potentially harmful, unnecessary evaluation of patients without true microhematuria.
虽然许多初级保健提供者提倡常规的尿分析筛查,但潜血阳性的尿液干化学试带检测往往会导致血尿(或假性血尿)的误诊。因此,美国泌尿外科学会指南建议,对于无症状患者,只有在至少 3 个高倍镜视野下有 3 个红细胞的 3 次显微镜尿分析中,才需要进行泌尿科评估。我们确定了因无症状性血尿而接受不必要咨询和检查的患者的比例。
如果患者因初始咨询就诊时诊断代码为 599.7X(血尿),则将其作为回顾性研究对象。在这些患者中,确定了因无症状性非肉眼血尿而接受评估的患者,并检查了转诊模式、辅助检查、操作和发现。
在 320 例新患者就诊中,诊断代码为 599.7X,其中 91 例因无症状性非肉眼血尿而转诊。这些患者中,只有 37 例(41%)在转诊前进行了显微镜尿分析,只有 22 例(24%)的显微镜尿分析显示每高倍镜视野有 3 个或更多红细胞。在未经确认的微血尿患者中,约有 25%的患者确实有微血尿,而在没有真正血尿的患者中,有 15 例在转诊前进行了影像学检查。这些患者的医疗保险报销费用为 44901 美元。在这些患者中,有 35 例行膀胱镜检查,只有 1 例(有真正的微血尿)患有恶性肿瘤。
在泌尿科转诊或评估之前,应始终通过显微镜尿分析来确认尿液干化学试带检测的潜血阳性结果。对转诊医生进行美国泌尿外科学会指南的教育,可能有助于限制对没有真正微血尿的患者进行昂贵且潜在有害的不必要评估。